advertisement
Value in Health 13
Showing records 1 to 13 | Display all abstracts in Value in Health46872 Quality of life in ocular hypertension and primary open angle glaucoma
Wolfram C; Lorenz K; Shlaen R; Verboven Y; Pfeiffer N
Value in Health 2010; 13: A402
46873 Safety profile of latanoprost versus timolol in patients with open angle glaucoma or ocular hypertension: Post 2000 setting
Gupta J; Siddiqui MK; Jindal R; Sehgal M
Value in Health 2011; 14: 54
46874 A discrete event simulation to optimise the allocation of constrained hospital resources for glaucoma
Crane GJ; Karnon J; Kymes S; Casson R; Metcalfe A; Hiller JE
Value in Health 2011; 14: A55
46878 Cost of glaucoma in the United Kingdom according to the UK GPRD
Salmon J; Lafuma A; Robert J; Berdeaux G
Value in Health 2010; 13: 398
46876 Cost-effectiveness analysis of travoprost followed by fixed combination travoprost/timolol treatment sequence (T-TTFC) compared to latanoprost followed by latanoprost/timolol fixed combination (L-LTFC) for patients with open angle glaucoma or ocular hyper
Taylor M; Tan R
Value in Health 2010; 13: 509
46871 Cost-effectiveness analysis of formulary management strategies for first-line agents used in open-angle glaucoma and ocular hypertension
Blaser DA; Ousterhout MM; Gagnon JM; Calabrese D
Value in Health 2011; 14: A55
46875 Burden of disease in patients with glaucoma in China: Results from 2009 national health and wellness survey
Tang B; Annunziata K; Zhong Z; Dong P; Xuan J
Value in Health 2010; 13: 562-563
46877 Costs and effects of fixed combination therapies in open angle glaucoma
Wickstrom J; Centofanti M; Johnson M
Value in Health 2010; 13: 399-400
46879 Costs of glaucoma in Sweden - A pilot study
Svensson J; Berdeaux G; Bergstrom A; Forsby M; Ghatnekar O
Value in Health 2010; 13: 399
46880 Development of a multiattribute instrument for estimating utilities (preference weights) in people with glaucoma from the national eye institute visual functioning questionnaire (NEI-VFQ)
Kymes S; Peters CM; Beusterien K; Kotak S; Grinspan J; Stwalley D; Pleil A
Value in Health 2011; 14: 56
46882 Glaucoma disease progression states: Establishing a direct, quantitative link between visual field defects and utility loss
Gerlier L; Lamotte M; Verboven Y
Value in Health 2010; 13: 248
46883 Predictive factors of glaucoma treatment cost in Germany
Lorenz K; Wolfram C; Claus V; Plesnila-Frank C; Verboven Y; Pfeiffer N
Value in Health 2010; 13: 398-399
46881 Cost-effectiveness of brinzolamide/timolol fixed combination (BTFC) versus dorzolamide/timolol fixed combination (DTFC) for patients with open angle glaucoma in Korea and Taiwan
Tan R
Value in Health 2010; 13: 563
